VEGFA and nonpapillary renal cell carcinoma: A 2016 study showed that PD-L1 expression at the time of diagnosis was 12.6% in patients with metastatic ccRCC, in which 50% of patients received vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitors (TKIs) therapy after surgery [42].